Madopar monotherapy ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04968613 (ClinicalTrials.gov) | January 1, 2018 | 27/6/2021 | Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease | Dopaminergic Mechanism of Temporal Working Memory Impairment in Parkinson's Disease | Parkinson Disease;Memory Impairment | Drug: Madopar monotherapy;Drug: senfrol monotherapy;Drug: placebo monotherapy | Peking University Third Hospital | Chinese Academy of Sciences | Recruiting | 50 Years | 80 Years | All | 150 | Phase 4 | China |